RecruitingPhase 2Phase 3NCT07369739

Golidocitinib Combined With Selinexor for CAEBVD

Golidocitinib Combined With Selinexor for the Treatment of Chronic Active Epstein-Barr Virus Disease (CAEBVD): A Multicenter, Prospective, Single-arm Clinical Study

Sponsor

Beijing Friendship Hospital

Enrollment

28 participants

Start Date

Jan 1, 2026

Study Type

INTERVENTIONAL

Conditions

EBV Lymphohistiocytosis CAEBV

Summary

This study is a multicenter, prospective, single-arm clinical investigation, with patients with CAEBVD as the main research subjects, to evaluate the effectiveness of the combined treatment regimen of golidocitinib and selinexor.

Eligibility

Min Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Selinexor (combination therapy) and a drug called golidocitinib for people with caebv, ebv, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 70 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.